GoldBamboo.com - Knowledge is strong medicine
  

Decitabine in Treating Patients With Myelodysplastic Syndrome - Article


  Not Signed In - Sign In / Register








Anemia

General anemia 



Clinical Trial: Decitabine in Treating Patients With Myelodysplastic Syndrome

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Memorial Sloan-Kettering Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of decitabine in treating patients with myelodysplastic syndrome.

Condition Treatment or Intervention Phase
de novo myelodysplastic syndrome
refractory anemia with excess blasts in transformation
refractory anemia with excess blasts
Refractory Anemia
Previously Treated Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
secondary myelodysplastic syndrome
refractory anemia with ringed sideroblasts
 Drug: decitabine
Phase II

MedlinePlus related topics:  Anemia;   Bone Marrow Diseases;   Leukemia, Adult Acute;   Leukemia, Adult Chronic;   Leukemia, Childhood

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Decitabine for Myelodysplastic Syndromes

Further Study Details: 

Study start: April 1998

OBJECTIVES: I. Determine the response of patients with myelodysplastic syndromes (including chronic myelomonocytic leukemia) to decitabine.

PROTOCOL OUTLINE: This is an open label, multicenter study. Patients are stratified by disease (low risk myelodysplastic syndrome (MDS) vs. high risk MDS vs. chronic myelomonocytic leukemia). Patients receive decitabine as a 4 hour infusion every 8 hours on days 1-3. Treatment continues every 6-8 weeks for 4-6 courses. Patients are followed at 6 and 12 months.

PROJECTED ACCRUAL: Approximately 75 patients will be accrued for this study over 1 year.

Eligibility

Ages Eligible for Study:  15 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Histologically proven myelodysplastic syndrome; Refractory anemia (RA) RA with ringed sideroblasts (RARS); RA with excess blasts (RAEB); RAEB in transformation; Chronic myelomonocytic leukemia (CMML)
  • RA and RARS: Platelet count less than 50,000/mm3
  • CMML: If WBC greater than 10,000/mm3, then must have at least 8% monocytes in the blood or marrow

--Prior/Concurrent Therapy--

  • Biologic therapy: Not specified
  • Chemotherapy: No more than one prior chemotherapy regimen for myelodysplastic syndromes; At least 3 weeks since chemotherapy and recovered; No prior high-dose cytarabine (at least 0.5 g/m2 for at least 4 doses)
  • Endocrine therapy: Not specified
  • Radiotherapy: Not specified
  • Surgery: Not specified

--Patient Characteristics--

  • Age: 15 and over
  • Performance status: Zubrod 0-2
  • Life expectancy: Not specified
  • Hematopoietic: See Disease Characteristics
  • Hepatic: Bilirubin no greater than 2.0 mg/dL
  • Renal: Creatinine no greater than 2.0 mg/dL
  • Cardiovascular: No New York Heart Association class III or IV heart disease
  • Other: No active or uncontrolled infection; Not pregnant or nursing; Fertile patients must use effective contraception; No other active cancer except skin cancer

Location Information


Maryland
      Johns Hopkins Oncology Center, Baltimore,  Maryland,  21231-2410,  United States

New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States

Texas
      University of Texas - MD Anderson Cancer Center, Houston,  Texas,  77030-4009,  United States

Study chairs or principal investigators

Stephen D. Nimer,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000066343; MSKCC-98017; NCI-G98-1444
Record last reviewed:  March 2004
Last Updated:  October 13, 2004
Record first received:  November 1, 1999
ClinicalTrials.gov Identifier:  NCT00003361
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Anemia.

April 25, 2014



Page Updated: October 15, 2009
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use

Copyright © 2004-2014 - Anaconda Partners LLC - All rights reserved.